Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.650
+0.090 (3.52%)
At close: Sep 26, 2025, 4:00 PM EDT
2.640
-0.010 (-0.38%)
After-hours: Sep 26, 2025, 7:40 PM EDT
Esperion Therapeutics Revenue
Esperion Therapeutics had revenue of $82.39M in the quarter ending June 30, 2025, with 11.58% growth. This brings the company's revenue in the last twelve months to $268.13M, down -3.48% year-over-year. In the year 2024, Esperion Therapeutics had annual revenue of $332.31M with 185.66% growth.
Revenue (ttm)
$268.13M
Revenue Growth
-3.48%
P/S Ratio
1.94
Revenue / Employee
$881,990
Employees
304
Market Cap
534.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332.31M | 215.98M | 185.66% |
| Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
| Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
| Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
| Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ESPR News
- 9 days ago - Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia - GlobeNewsWire
- 20 days ago - Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 22 days ago - Top 2 Health Care Stocks That May Plunge This Month - Benzinga
- 4 weeks ago - Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias - GlobeNewsWire
- 7 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Esperion to Report Second Quarter 2025 Financial Results on August 5 - GlobeNewsWire